Back
IMKHC
Interstar Millennium Series 2004-2G Trust
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cl.B Usd Frn.Mort.Backed Min.Con.Usd1Ht Non Chess
📈 Performance
N/A
N/A
31st May 2023, 12:00 a.m.
1M
All Time
GRAPH
TABLE
GRAPH
TABLE
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IMKHC
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in IMKHC
N/A
IMKHC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in IMKHC also invest in...
Want more shares? Try these...
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. The firm has three clinical and one pre-clinical LAG-3-related product candidates under development, including two antibodies for modulating immune responses in cancer and autoimmunity. Its lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), an antigen-presenting cell (APC) activator, which is being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for various cancer indications, including IMP761, which is preclinical immunotherapy for autoimmune disease; LAG525 or leramilimab (IMP701), which is immunotherapy for solid tumors, blood cancer and breast cancer, and GSK‘781 (IMP731), which is immunotherapy in autoimmune diseases. Its subsidiaries include Immutep USA Inc, Immutep GmbH, Immutep Australia Pty Ltd and Immutep S.A.S.
📊 Share price
